PFIZER’S CENTERS FOR THERAPEUTIC INNOVATION (CTI)

REQUEST FOR TRANSLATIONAL PROPOSALS FOR BIOTHERAPEUTIC TARGETS

Proposal Deadline: May 16, 2014

CTI: an innovative Pfizer program that partners with leading academic medical centers and foundations nationwide to accelerate the translation of novel targets to the clinic. CTI’s goal is to identify new compounds and accelerate research and drug development from validated target to proof-of-mechanism in the clinic. A partnership with CTI includes collaborative use of Pfizer’s proprietary antibody drug discovery tools and technologies, broad publishing rights and significant financial awards in the form of milestone and royalty payments for successful programs.

Therapeutic Areas of Interest:
› Inflammation, autoimmunity, tissue remodeling, oncology, rare or genetic diseases, neuroscience, cardiovascular and metabolic diseases
› In this call, CTI especially seeks new partnerships in immunoregulation in autoimmune disease and cancer to either harness the immune system for tumor eradication or, conversely, targeted therapies to provide selective immunosuppression or immunoregulation for autoimmune diseases
› For cancer immunotherapy, this may involve mechanisms to target T Regulatory cells, myeloid suppressor cells or other immune augmentation strategies
› For the treatment of autoimmune disease, we are interested in novel approaches to treat a variety of diseases associated with immune dysregulation, including proposals describing intervention points to drive the development of immunological tolerance and de novo generation and/or functional enhancement of T regulatory cells

What We Look For:
› Targets that are tractable with biologics (i.e. surface proteins, secreted proteins)
  ▪ Strong link from targeted pathway to disease
  ▪ Opportunity to address unmet medical need
› Differentiators such as:
  ▪ Ability to elucidate path to proof-of-mechanism in humans
  ▪ Clinical differentiation opportunity via patient stratification, molecular signatures, genetic associations and biomarkers
› Biologics for the treatment of rheumatoid arthritis and psoriasis are out of scope for this proposal.

All researchers, clinicians and post-docs whose work meets these criteria are invited to apply.
For more information about submitting a proposal, please contact Ece Auffarth, Ece.Auffarth@einstein.yu.edu